Evolent Health Stock Plummets to New 52-Week Low of $6.58

Evolent Health, Inc. has reached a new 52-week low, trading at USD 6.58 as of October 30, 2025. This marks a significant decline for the small-cap company, which has seen its stock price plummet by 72.18% over the past year, contrasting sharply with the S&P 500's performance of 18.13% during the same period.
The company's financial metrics reveal a challenging landscape, with a market capitalization of USD 1,151 million and a return on equity of -10.28%. Evolent Health has reported negative results for three consecutive quarters, with pre-tax profits falling by 355.12% and net profits decreasing by 311.27%. Additionally, the operating cash flow has reached a low of USD -33.32 million, indicating ongoing financial difficulties.

Evolent Health's price-to-book ratio stands at 1.28, while the company carries a debt-to-equity ratio of 1.00. These figures, combined with a lack of dividend yield, highlight the company's current struggles in maintaining profitability and operational efficiency. The stock's performance continues to reflect a consistent underperformance against market benchmarks over the last three years.